<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MIDAZOLAM HYDROCHLORIDE</span><br/>(mid'az-zoe-lam)<br/><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">benzodiazepine anxiolytic</span>; <span class="classification">sedative-hypnotic</span><br/><b>Prototype: </b>Lorazepam<br/><b>Pregnancy Category: </b>D<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg/mL syrup; 1 mg/mL, 5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Short-acting parenteral benzodiazepine. Mechanism of action unclear. Intensifies activity of gamma-aminobenzoic acid (GABA),
         a major inhibitory neurotransmitter of the brain, by interfering with its reuptake and promoting its accumulation at neuronal
         synapses. This calms the patient, relaxes skeletal muscles, and in high doses produces sleep.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>CNS depressant with muscle relaxant, sedative-hypnotic, anticonvulsant, and amnestic properties.</p>
<h1><a name="uses">Uses</a></h1>
<p>Sedation before general anesthesia, induction of general anesthesia; to impair memory of perioperative events (anterograde
         amnesia); for conscious sedation prior to short diagnostic and endoscopic procedures; and as the hypnotic supplement to nitrous
         oxide and oxygen (balanced anesthesia) for short surgical procedures.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Intolerance to benzodiazepines; acute narrow-angle glaucoma; shock, coma; acute alcohol intoxication; intraarterial injection.
         Safety in pregnancy (category D), labor and delivery, or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patient with COPD; chronic kidney failure; CHF; the older adult.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Conscious Sedation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 0.070.08 mg/kg 3060 min before procedure <span class="rdroute">IV</span> 11.5 mg, may repeat in 2 min prn; <i>Intubated Patients,</i> 0.050.2 mg/kg/h by continuous infusion<br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> 0.08 mg/kg times 1 dose <span class="rdroute">PR</span> 0.3 mg/kg times 1 dose; <i>Intubated Patients,</i> 2 mcg/kg/min by continuous infusion, may increase by 1 mcg/kg/min q30 min until light sleep is induced<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 0.51 mcg/kg/min<br/><br/><span class="indicationtitle">IV Induction for General Anesthesia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span>
<i>Premedicated,</i> 0.150.25 mg/kg over 2030 s, allow 2 min for effect <span class="rdroute">IV</span>
<i>Nonpremedicated,</i> 0.30.35 mg/kg over 2030 s, allow 2 min for effect<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.15 mg/kg followed by 0.05 mg/kg q2 min times 13 doses<br/><br/><span class="indicationtitle">Status Epilepticus</span><br/><span class="rdage">Child:</span> <span class="rdroute">IV Loading Dose</span>
<i>&gt;2 mo,</i> 0.15 mg/kg <span class="rdroute">IV Maintenance Dose</span> 1 mcg/kg/min infusion, may titrate upward as needed q5min<br/><br/><span class="indicationtitle">Preoperative Sedation</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i> 0.5 mg/kg; <i>&gt;5 y,</i> 0.40.5 mg/kg<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Inject IM drug deep into a large muscle mass.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute in D5W or NS to a concentration of 0.25 mg/mL (e.g., 1 mg in 4 mL or 5 mg in 20 mL)  <span class="methodtype">IV Infusion:</span> Add 5 mL of the 5 mg/mL concentration to 45 mL of D5W or NS to yield 0.5 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span>
<i> Sedation,</i> Give over <img src="../images/special/greaterorequal.gif"/>2 min; 
                  							<i>Induction of Anesthesia,</i> Give over 2030 sec.  <span class="methodtype">IV Infusion:</span> Give at a rate based on weight.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Lactated Ringer's, dimenhydrinate, pentobarbital, perphenazine, prochlorperazine, ranitidine.</b>
<span class="incompattype">Y-site:</span>
<b>Albumin, amoxicillin, amoxicillin/clavulanate, amphotericin B cholesteryl complex, ampicillin, bumetanide, butorphanol, ceftazidime,
                     cefuroxime, clonidine, dexamethasone, dimenhydrinate, floxacillin, foscarnet, fosphenytoin, furosemide, hydrocortisone, imipenem/cilastatin,
                     methotrexate, nafcillin, omeprazole, pentobarbital, perphenazine, prochlorperazine, sodium bicarbonate, thiopental, TPN.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F), therapeutic activity is retained for 2 y from date of manufacture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Retrograde amnesia,</span> headache, euphoria, drowsiness, excessive sedation, confusion. <span class="typehead">CV:</span> Hypotension. <span class="typehead">Special Senses:</span> Blurred vision, diplopia, nystagmus, pinpoint pupils. <span class="typehead">GI:</span> Nausea, vomiting. <span class="typehead">Respiratory:</span> Coughing, <span class="speceff-life">laryngospasm</span> (rare), <span class="speceff-life">respiratory arrest</span>. <span class="typehead">Skin:</span> Hives, swelling, burning, pain, induration at injection site, tachypnea. <span class="typehead">Body as a Whole:</span> Hiccups, chills, weakness. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol,</b>
<span class="classification">cns depressants</span>, <span class="classification">anticonvulsants</span> potentiate CNS depression; <b>cimetidine</b> increases midazolam plasma levels, increasing its toxicity; may decrease antiparkinsonism effects of <b>levodopa;</b> may increase <b>phenytoin</b> levels; <b>smoking</b> decreases sedative and antianxiety effects. <span class="typehead">Herbal:</span>
<b>Kava-kava,</b>
<b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span> 15 min IV; 515 min IM, 2030 min PO. <span class="typehead">Peak:</span> 2060 min. <span class="typehead">Duration:</span> Distribution: Crosses bloodbrain barrier and placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 14 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Inspect insertion site for redness, pain, swelling, and other signs of extravasation during IV infusion.</li>
<li>Monitor for hypotension, especially if the patient is premedicated with a narcotic agonist analgesic.</li>
<li>Monitor vital signs for entire recovery period. In obese patient, half-life is prolonged during IV infusion; therefore, duration
            of effects is prolonged (i.e., amnesia, postoperative recovery).
         </li>
<li>Be aware that overdose symptoms include somnolence, confusion, sedation, diminished reflexes, coma, and untoward effects on
            vital signs.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known. You may feel drowsy, weak, or
            tired for 12 d after drug has been given.
         </li>
<li>Be prepared for amnesia to prevent an upsetting postoperative period.</li>
<li>Review written instructions to assure future understanding and compliance. Patient teaching during amnestic period may not
            be remembered. Even if dose is small and depth of amnesia is unclear, relearn information.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>